Caribou Biosciences (NASDAQ:CRBU) Releases Earnings Results, Beats Expectations By $0.06 EPS

Caribou Biosciences (NASDAQ:CRBU) posted its quarterly earnings results on Wednesday. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06, Zacks reports. The business had revenue of $2.02 million for the quarter, compared to analysts’ expectations of $3.37 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 43.47%.

Caribou Biosciences Stock Down 3.6 %

Shares of CRBU traded down $0.10 during mid-day trading on Friday, reaching $2.68. 2,467,955 shares of the stock traded hands, compared to its average volume of 1,257,875. The stock has a fifty day simple moving average of $2.01 and a 200 day simple moving average of $2.30. Caribou Biosciences has a 12-month low of $1.50 and a 12-month high of $8.33. The firm has a market cap of $242.16 million, a price-to-earnings ratio of -1.62 and a beta of 2.26.

Wall Street Analyst Weigh In

Several research firms have commented on CRBU. Royal Bank of Canada restated an “outperform” rating and issued a $14.00 price target on shares of Caribou Biosciences in a report on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Caribou Biosciences in a report on Tuesday, September 3rd.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.